SCHEMBL6205081

SCHEMBL6205081

CNC(=O)CC(C)(C)C(N)=O

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515480 0.81 HDAC3 (0.37) LMNA
SCHEMBL13544805 0.78 MCL1 (0.36) MCL1LMNA
SCHEMBL13544539 0.78 TSHR (0.39) MCL1LMNA
SCHEMBL27417493 0.77 MCL1 (0.32) MCL1LMNA
SCHEMBL1515459 0.77
SCHEMBL6944057 0.75
SCHEMBL14167250 0.74 MCL1 (0.33) MCL1LMNA
SCHEMBL1515653 0.74 CNR1 (0.35) LMNA
SCHEMBL960674 0.74 KDM4E (0.40) LMNA
SCHEMBL681118 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3621619-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN Arena Pharmaceuticals, Inc. (US) 2020-03-18 EP claimed
WO-2018208848-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VISCERAL PAIN ARENA PHARMACEUTICALS, INC. (US) 2018-11-15 WO claimed
WO-2018208847-A1 COMPOUNDS AND METHODS FOR TREATMENT OF PAIN FROM INFLAMMATORY BOWEL DISEASE ARENA PHARMACEUTICALS, INC. (US) 2018-11-15 WO claimed
EP-2928867-A1 PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS F. Hoffmann-La Roche AG (CH) 2015-10-14 EP claimed
EP-2771327-A1 NOVEL PYRAZINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2014-09-03 EP claimed
WO-2014086805-A1 PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2014-06-12 WO claimed
WO-2013060751-A1 NOVEL PYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-05-02 WO claimed
EP-2470508-A1 CANNABINOID RECEPTOR MODULATORS Arena Pharmaceuticals, Inc. (US) 2012-07-04 EP claimed
EP-1532132-A1 NOVEL BENZODIOXOLES F.HOFFMANN-LA ROCHE AG (CH) 2005-05-25 EP claimed
US-6818622-B2 ADMINISTERING OVER A PERIOD OF AT LEAST THREE MONTHS A MATRIX METALLOPROTEINASE INHIBITOR FOR TREATMENT OF A PATIENT HAVING CANCER OR INFLAMMATION DARWIN DISCOVERY LTD. (GB) 2004-11-16 US claimed
EP-0981366-B1 SELECTIVE MMP INHIBITORS HAVING REDUCED SIDE-EFFECTS DARWIN DISCOVERY LTD (GB) 2004-01-21 EP claimed
US-20020173530-A1 Single morphic forms of metalloproteinase inhibitors KATZ RUTH BERNICE (GB) 2002-11-21 US claimed
US-20020035065-A1 Selective MMP inhibitors having reduced side-effects BIRD JOHN (GB) 2002-03-21 US claimed
US-20020025980-A1 Single morphic forms of metalloproteinase inhibitors KATZ RUTH BERNICE (GB) 2002-02-28 US claimed
US-6277827-B1 Single morphic forms of metalloproteinase inhibitors DARWIN DISCOVERY, LTD. (GB) 2001-08-21 US claimed
EP-1123308-A1 SINGLE MORPHIC FORMS OF KNOWN PEPTIDE METALLOPROTEINASE INHIBITORS Darwin Discovery Limited (GB) 2001-08-16 EP claimed
WO-2000024763-A1 SINGLE MORPHIC FORMS OF KNOWN PEPTIDE METALLOPROTEINASE INHIBITORS DARWIN DISCOVERY LIMITED (GB) 2000-05-04 WO claimed
EP-0763012-B1 SUCCINYL HYDROXAMIC ACID, N-FORMYL-N-HYDROXY AMINO CARBOXYLIC ACID AND SUCCINIC ACID AMIDE DERIVATIVES AS METALLOPROTEASE INHIBITORS BRITISH BIOTECH PHARM (GB) 1999-06-09 EP claimed
EP-0763012-A1 SUCCINYL HYDROXAMIC ACID, N-FORMYL-N-HYDROXY AMINO CARBOXYLIC ACID AND SUCCINIC ACID AMIDE DERIVATIVES AS METALLOPROTEASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1997-03-19 EP claimed
WO-1995032944-A1 SUCCINYL HYDROXAMIC ACID, N-FORMYL-N-HYDROXY AMINO CARBOXYLIC ACID AND SUCCINIC ACID AMIDE DERIVATIVES AS METALLOPROTEASE INHIBITORS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1995-12-07 WO claimed